



Shield Therapeutics plc
("Shield" or the "Group")

2020 Annual Report and 2021 AGM Notice

London, UK, 13 May 2021: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with an initial focus on addressing iron deficiency, announces that the following documents have now been sent to shareholders:

- Annual Report and Accounts for the year ended 31 December 2020
- Notice of Annual General Meeting ("AGM") 2021

In accordance with AIM Rule 26, these documents are also available to view on the Company's website www.shieldtherapeutics.com/investors/corporate-documents/.

The AGM is scheduled to be held at 2.00pm BST on Thursday 17 June 2021. Due to the continuing COVID-19 restrictions, this meeting will be held virtually, and attendance will be available online and telephonically.

The Company will provide a facility for shareholders to join the AGM online and telephonically and there will be an opportunity for shareholders to ask questions. In order to facilitate the process, the Board would request that shareholders register for the meeting and submit questions in advance, before 2.00pm (BST) on 15 June 2021.

To register for dial-in details and to submit any questions please contact Walbrook PR via email at shield@walbrookpr.com or call +44 (0)20 7933 8787.

For further information, please contact:

Shield Therapeutics plc Tim Watts (CEO) Lucy Huntington-Bailey (Company Secretary and General Counsel)	+44 (0) 191 511 8500
Peel Hunt LLP – Nominated Adviser & Joint Broker James Steel / Christopher Golden	+44 (0) 20 7148 8900
finnCap Ltd - Joint Broker Geoff Nash / Alice Lane / Matthew Radley	+44 (0) 20 7220 0500
Walbrook PR – Financial PR & IR Adviser Paul McManus / Lianne Cawthorne	+44 (0) 20 7933 8780 or shield@walbrookpr.com

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru[®] /Accrufer[®] (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Shield's lead product, Feraccru[®]/Accrufer[®], has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer[®] in the US during 2021 through a highly experienced sales and marketing team. Feraccru[®] is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand.

Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru[®]/Accrufer[®] in China, Hong Kong, Macau and Taiwan.

For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx